CCFM
TGTX icon

Clear Creek Financial Management’s TG Therapeutics TGTX Stock Holding History

Clear Creek Financial Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,850
Closed -$335K – 478
2024
Q2 		$335K Sell
18,850
-1,000
-5% -$16K 0.04% 318
2024
Q1 		$302K Buy
19,850
+500
+3% +$7.96K 0.04% 326
2023
Q4 		$330K Sell
19,350
-750
-4% -$8.72K 0.05% 250
2023
Q3 		$168K Buy
+20,100
New +$280K 0.03% 306

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Creek Financial Management's TGTX Position: Q3 2024 in Review

Clear Creek Financial Management sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 18,850 shares — an estimated $335K sold.

Clear Creek Financial Management first reported a position in TGTX in Q3 2023 and held it in 4 quarters. The position peaked at $335K in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Clear Creek Financial Management reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Clear Creek Financial Management sold 18,850 TG Therapeutics shares in Q3 2024, an estimated $335K.
  • Clear Creek Financial Management first reported a position in TG Therapeutics in Q3 2023 and held it in 4 quarters.
  • Clear Creek Financial Management's TG Therapeutics position peaked at $335K in Q2 2024.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Clear Creek Financial Management's 13F filing for Q3 2024, filed 29 Oct 2024.